Vimal Kumar
Research Subjects
Vimal Kumar has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Deenadayalan Munirathnam
Department of Pediatric Hematology, Oncology, Blood and Marrow Transplantation MGM Cancer Institute Chennai India
7 shared publications Deenadayalan Munirathnam
Department of Pediatric Hematology Oncology, Blood and Marrow Transplantation MGM Cancer Institute Chennai India
6 shared publicationsMohamed Rela
Institute of HPB surgery and Liver Transplantation, Dr Rela Institute and Medical Centre, Chennai, India
3 shared publicationsNaresh Shanmugam
Department of Pediatric Gastroenterology and Hepatology, Dr Rela Institute and Medical Centre, Chennai, India
3 shared publicationsRishab Bharadwaj
Department of Pediatric Hematology, Oncology & BMT, MGM Cancer Institute, Chennai, India
3 shared publications- Rishab Bharadwaj
Department of Pediatric Hematology Oncology, Blood and Marrow Transplantation MGM Cancer Institute Chennai India
3 shared publications
Latest Publications
- 28 July 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (3) , 1099-1101
Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Recipients of Liver Transplantation (LT)– An Orchestration Of Immune Chimera
- 28 July 2025
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 42 (3) , 1099-1101
Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) in Recipients of Liver Transplantation (LT)– An Orchestration Of Immune Chimera
- 12 June 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (9) , e31837
Successful Haploidentical Haematopoietic Stem Cell Transplant in a Rare Case of Bloom Syndrome Associated With Monosomy 7/MDS
- 12 June 2025
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 72 (9) , e31837
Successful Haploidentical Haematopoietic Stem Cell Transplant in a Rare Case of Bloom Syndrome Associated With Monosomy 7/MDS
- 20 June 2023
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (2) , 335-339
A Single Centre Experience of Effective Desensitization Strategy for Children with High Anti-HLA Donor-Specific Antibodies Undergoing Haploidentical Hematopoietic Stem Cell Transplantation
To assess the incidence of anti-HLA donor-specific antibodies and the effectiveness of desensitization strategy in children who underwent haploidentical HSCT at our hospital. A retrospective review, management and outcomes of children with positive anti-HLA DSA who underwent haploidentical HSCT at our hospital from 2020 to 2022. Three patients with Thalassemia major were treated with 2 cycles of pretransplant immune suppression (PTIS) comprising Fludarabine and Dexamethasone in addition to desensitization. Five out of the 26 children who underwent haploidentical HSCT had positive anti-HLA DSA. Post desensitization, three out of the 5 children engrafted with sustained full donor chimerism, 1 patient developed primary graft rejection, while 1 patient died. It is feasible to desensitize children with high anti-HLA donor specific antibodies undergoing haploidentical HSCT to improve outcomes.
- 20 June 2023
- Published by Springer Nature in Indian Journal of Hematology and Blood Transfusion
- Vol. 40 (2) , 335-339
A Single Centre Experience of Effective Desensitization Strategy for Children with High Anti-HLA Donor-Specific Antibodies Undergoing Haploidentical Hematopoietic Stem Cell Transplantation
To assess the incidence of anti-HLA donor-specific antibodies and the effectiveness of desensitization strategy in children who underwent haploidentical HSCT at our hospital. A retrospective review, management and outcomes of children with positive anti-HLA DSA who underwent haploidentical HSCT at our hospital from 2020 to 2022. Three patients with Thalassemia major were treated with 2 cycles of pretransplant immune suppression (PTIS) comprising Fludarabine and Dexamethasone in addition to desensitization. Five out of the 26 children who underwent haploidentical HSCT had positive anti-HLA DSA. Post desensitization, three out of the 5 children engrafted with sustained full donor chimerism, 1 patient developed primary graft rejection, while 1 patient died. It is feasible to desensitize children with high anti-HLA donor specific antibodies undergoing haploidentical HSCT to improve outcomes.
- 1 November 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (1) , e30024
Outcomes of liver transplantation in children with Langerhans cell histiocytosis: Experience from a quaternary care center
Background: Langerhans cell histiocytosis (LCH) is a rare but important cause of end‐stage liver disease in children. Conventional chemotherapeutic agents that are otherwise the standard‐of‐care in LCH may be counterproductive in patients with hepatic decompensation. Furthermore, the precise role of liver transplantation (LT) in the management of LCH remains unclear.Methods: Review of a prospectively collected database (January 2014 to December 2020) of children with liver disease was performed. All clinical details of patients with LCH managed at our center were collected and data analyzed. Based on the outcomes, a management algorithm was proposed.Results: Of the eight (five male) patients referred to our unit, six (75%) underwent LT (four and two for compensated and decompensated cirrhosis, respectively). Median age at diagnosis of LCH was 25 (range: 9–48) months. Two patients, who had previously completed LCH‐specific chemotherapy, underwent upfront LT for compensated cirrhosis. Other two patients with compensated cirrhosis showed evidence of active disease. They underwent LT following completion of chemotherapy. Two children with decompensated cirrhosis also had evidence of active disease and were started on modified chemotherapy Both of them had progression of liver disease while on chemotherapy. Hence, an urgent LT was performed which was followed by completion of chemotherapy in these patients. On a median follow‐up of 30.5 (10.5–50) months, all post‐LT patients were alive with stable graft function and showed no disease recurrence.Conclusion: We demonstrate that an algorithmic approach, along with newer chemotherapeutic agents, results in excellent outcomes in LCH patients with liver involvement. Larger multicentric studies on this rare disease are, however, needed to validate our findings.
- 1 November 2022
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (1) , e30024
Outcomes of liver transplantation in children with Langerhans cell histiocytosis: Experience from a quaternary care center
Background: Langerhans cell histiocytosis (LCH) is a rare but important cause of end‐stage liver disease in children. Conventional chemotherapeutic agents that are otherwise the standard‐of‐care in LCH may be counterproductive in patients with hepatic decompensation. Furthermore, the precise role of liver transplantation (LT) in the management of LCH remains unclear.Methods: Review of a prospectively collected database (January 2014 to December 2020) of children with liver disease was performed. All clinical details of patients with LCH managed at our center were collected and data analyzed. Based on the outcomes, a management algorithm was proposed.Results: Of the eight (five male) patients referred to our unit, six (75%) underwent LT (four and two for compensated and decompensated cirrhosis, respectively). Median age at diagnosis of LCH was 25 (range: 9–48) months. Two patients, who had previously completed LCH‐specific chemotherapy, underwent upfront LT for compensated cirrhosis. Other two patients with compensated cirrhosis showed evidence of active disease. They underwent LT following completion of chemotherapy. Two children with decompensated cirrhosis also had evidence of active disease and were started on modified chemotherapy Both of them had progression of liver disease while on chemotherapy. Hence, an urgent LT was performed which was followed by completion of chemotherapy in these patients. On a median follow‐up of 30.5 (10.5–50) months, all post‐LT patients were alive with stable graft function and showed no disease recurrence.Conclusion: We demonstrate that an algorithmic approach, along with newer chemotherapeutic agents, results in excellent outcomes in LCH patients with liver involvement. Larger multicentric studies on this rare disease are, however, needed to validate our findings.
- Open Access
- 2 May 2022
- Published by Wiley
Outcomes of Liver transplantation in children with Langerhans Cell Histiocytosis: Experience from a quaternary care centre and an algorithmic approach
Objective : Spectrum of hepatic presentation in Langerhans cell histiocytosis (LCH) varies from asymptomatic hepatomegaly to secondary sclerosing cholangitis leading to cirrhosis with or without decompensation. Conventional chemotherapy may be counterproductive in a patient with LCH and hepatic decompensation. We analysed the outcomes of our patients with hepatic presentation of LCH, including their post liver transplant (LT) follow up. Methods: A retrospective analysis was performed on patients with hepatic presentation of LCH referred to our unit. Their clinical profile, chemotherapy protocol, details of LT and survival were analysed. A management algorithm based on the outcomes was proposed. Results: Five of 8 patients were male. Median age of diagnosis was 25(9-48) months. 8(100%) patients had portal hypertension with 4(50%) having decompensated cirrhosis. 6 (75%) patients underwent LT of which 2 had acute decompensation and 4 had sclerosing cholangitis with portal hypertension. Of the two remaining patients, 1 did not tolerate chemotherapy and succumbed, whereas 1 patient after first cycle of chemotherapy was lost to follow up. As their liver disease was worsening during chemotherapy (after 8 & 20 weeks of chemotherapy), two patients underwent urgent LT followed by continuation of chemotherapy. After median follow-up of 30.5 (10.5-50) months, all patients were alive with stable graft function and no disease recurrence. Conclusion: As shown in our series, an algorithmic approach to patient and treatment selection for LCH patients with liver involvement combined with newer chemotherapeutic agents and an optimized immunosuppression can result in excellent outcomes for a hitherto unfamiliar disease.
- 2 May 2022
- Published by Wiley
Open AccessOutcomes of Liver transplantation in children with Langerhans Cell Histiocytosis: Experience from a quaternary care centre and an algorithmic approach
Objective : Spectrum of hepatic presentation in Langerhans cell histiocytosis (LCH) varies from asymptomatic hepatomegaly to secondary sclerosing cholangitis leading to cirrhosis with or without decompensation. Conventional chemotherapy may be counterproductive in a patient with LCH and hepatic decompensation. We analysed the outcomes of our patients with hepatic presentation of LCH, including their post liver transplant (LT) follow up. Methods: A retrospective analysis was performed on patients with hepatic presentation of LCH referred to our unit. Their clinical profile, chemotherapy protocol, details of LT and survival were analysed. A management algorithm based on the outcomes was proposed. Results: Five of 8 patients were male. Median age of diagnosis was 25(9-48) months. 8(100%) patients had portal hypertension with 4(50%) having decompensated cirrhosis. 6 (75%) patients underwent LT of which 2 had acute decompensation and 4 had sclerosing cholangitis with portal hypertension. Of the two remaining patients, 1 did not tolerate chemotherapy and succumbed, whereas 1 patient after first cycle of chemotherapy was lost to follow up. As their liver disease was worsening during chemotherapy (after 8 & 20 weeks of chemotherapy), two patients underwent urgent LT followed by continuation of chemotherapy. After median follow-up of 30.5 (10.5-50) months, all patients were alive with stable graft function and no disease recurrence. Conclusion: As shown in our series, an algorithmic approach to patient and treatment selection for LCH patients with liver involvement combined with newer chemotherapeutic agents and an optimized immunosuppression can result in excellent outcomes for a hitherto unfamiliar disease.
- 2 November 2021
- Published by Taylor & Francis in Fetal and Pediatric Pathology
- Vol. 41 (6) , 1023-1034
CARMIL2 Immunodeficiency with Epstein Barr Virus Associated Smooth Muscle Tumor (EBV-SMT). Report of a Case with Comprehensive Review of Literature
Background: Primary immunodeficiency (PID) having defects related to lymphocyte cytotoxic pathway or T-cell dysfunction are well known for developing opportunistic infections and Epstein-Barr virus (EBV)-associated diseases. CARMIL2 deficiency is a recently described combined immunodeficiency (CID) disorder characterized by defective CD28-mediated T cell co-stimulation, altered cytoskeletal dynamics, susceptibility to various infections and Epstein Barr Virus smooth muscle tumor (EBV-SMT). Case report: We report a homozygous CARMIL2 pathogenic variant presenting with recurrent infections and EBV associated smooth muscle tumor (SMT) in a child. Conclusion: The present study reports that EBV SMT may occur in a child with CARMIL2 deficiency.
- 2 November 2021
- Published by Taylor & Francis in Fetal and Pediatric Pathology
- Vol. 41 (6) , 1023-1034
CARMIL2 Immunodeficiency with Epstein Barr Virus Associated Smooth Muscle Tumor (EBV-SMT). Report of a Case with Comprehensive Review of Literature
Background: Primary immunodeficiency (PID) having defects related to lymphocyte cytotoxic pathway or T-cell dysfunction are well known for developing opportunistic infections and Epstein-Barr virus (EBV)-associated diseases. CARMIL2 deficiency is a recently described combined immunodeficiency (CID) disorder characterized by defective CD28-mediated T cell co-stimulation, altered cytoskeletal dynamics, susceptibility to various infections and Epstein Barr Virus smooth muscle tumor (EBV-SMT). Case report: We report a homozygous CARMIL2 pathogenic variant presenting with recurrent infections and EBV associated smooth muscle tumor (SMT) in a child. Conclusion: The present study reports that EBV SMT may occur in a child with CARMIL2 deficiency.
- Open Access
- 27 October 2021
- Published by Springer Nature in Indian Pediatrics
- Vol. 58 (10) , 993-994
Hereditary Non-Spherocytic Hemolytic Anemia (HNSHA): Four Children with Rare Hereditary Red Cell Enzymopathies
- 27 October 2021
- Published by Springer Nature in Indian Pediatrics
- Vol. 58 (10) , 993-994
Open AccessHereditary Non-Spherocytic Hemolytic Anemia (HNSHA): Four Children with Rare Hereditary Red Cell Enzymopathies